Cargando…

Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome

Over the past 20 years, exposure to mycotoxin producing mold has been recognized as a significant health risk. Scientific literature has demonstrated mycotoxins as possible causes of human disease in water-damaged buildings (WDB). This study was conducted to determine if selected mycotoxins could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Brewer, Joseph H., Thrasher, Jack D., Straus, David C., Madison, Roberta A., Hooper, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705282/
https://www.ncbi.nlm.nih.gov/pubmed/23580077
http://dx.doi.org/10.3390/toxins5040605
_version_ 1782476409149587456
author Brewer, Joseph H.
Thrasher, Jack D.
Straus, David C.
Madison, Roberta A.
Hooper, Dennis
author_facet Brewer, Joseph H.
Thrasher, Jack D.
Straus, David C.
Madison, Roberta A.
Hooper, Dennis
author_sort Brewer, Joseph H.
collection PubMed
description Over the past 20 years, exposure to mycotoxin producing mold has been recognized as a significant health risk. Scientific literature has demonstrated mycotoxins as possible causes of human disease in water-damaged buildings (WDB). This study was conducted to determine if selected mycotoxins could be identified in human urine from patients suffering from chronic fatigue syndrome (CFS). Patients (n = 112) with a prior diagnosis of CFS were evaluated for mold exposure and the presence of mycotoxins in their urine. Urine was tested for aflatoxins (AT), ochratoxin A (OTA) and macrocyclic trichothecenes (MT) using Enzyme Linked Immunosorbent Assays (ELISA). Urine specimens from 104 of 112 patients (93%) were positive for at least one mycotoxin (one in the equivocal range). Almost 30% of the cases had more than one mycotoxin present. OTA was the most prevalent mycotoxin detected (83%) with MT as the next most common (44%). Exposure histories indicated current and/or past exposure to WDB in over 90% of cases. Environmental testing was performed in the WDB from a subset of these patients. This testing revealed the presence of potentially mycotoxin producing mold species and mycotoxins in the environment of the WDB. Prior testing in a healthy control population with no history of exposure to a WDB or moldy environment (n = 55) by the same laboratory, utilizing the same methods, revealed no positive cases at the limits of detection.
format Online
Article
Text
id pubmed-3705282
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37052822013-07-09 Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome Brewer, Joseph H. Thrasher, Jack D. Straus, David C. Madison, Roberta A. Hooper, Dennis Toxins (Basel) Article Over the past 20 years, exposure to mycotoxin producing mold has been recognized as a significant health risk. Scientific literature has demonstrated mycotoxins as possible causes of human disease in water-damaged buildings (WDB). This study was conducted to determine if selected mycotoxins could be identified in human urine from patients suffering from chronic fatigue syndrome (CFS). Patients (n = 112) with a prior diagnosis of CFS were evaluated for mold exposure and the presence of mycotoxins in their urine. Urine was tested for aflatoxins (AT), ochratoxin A (OTA) and macrocyclic trichothecenes (MT) using Enzyme Linked Immunosorbent Assays (ELISA). Urine specimens from 104 of 112 patients (93%) were positive for at least one mycotoxin (one in the equivocal range). Almost 30% of the cases had more than one mycotoxin present. OTA was the most prevalent mycotoxin detected (83%) with MT as the next most common (44%). Exposure histories indicated current and/or past exposure to WDB in over 90% of cases. Environmental testing was performed in the WDB from a subset of these patients. This testing revealed the presence of potentially mycotoxin producing mold species and mycotoxins in the environment of the WDB. Prior testing in a healthy control population with no history of exposure to a WDB or moldy environment (n = 55) by the same laboratory, utilizing the same methods, revealed no positive cases at the limits of detection. MDPI 2013-04-11 /pmc/articles/PMC3705282/ /pubmed/23580077 http://dx.doi.org/10.3390/toxins5040605 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Brewer, Joseph H.
Thrasher, Jack D.
Straus, David C.
Madison, Roberta A.
Hooper, Dennis
Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title_full Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title_fullStr Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title_full_unstemmed Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title_short Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome
title_sort detection of mycotoxins in patients with chronic fatigue syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705282/
https://www.ncbi.nlm.nih.gov/pubmed/23580077
http://dx.doi.org/10.3390/toxins5040605
work_keys_str_mv AT brewerjosephh detectionofmycotoxinsinpatientswithchronicfatiguesyndrome
AT thrasherjackd detectionofmycotoxinsinpatientswithchronicfatiguesyndrome
AT strausdavidc detectionofmycotoxinsinpatientswithchronicfatiguesyndrome
AT madisonrobertaa detectionofmycotoxinsinpatientswithchronicfatiguesyndrome
AT hooperdennis detectionofmycotoxinsinpatientswithchronicfatiguesyndrome